The pharmaceutical industry uses IBC totes for raw material receiving, intermediate storage, and finished product holding. The stakes are high — contamination of pharmaceutical ingredients can harm patients and trigger costly recalls. Good Manufacturing Practice (GMP) regulations under 21 CFR Parts 210 and 211 impose strict requirements on containers used in pharmaceutical production, and these requirements go far beyond what is expected in food-grade or industrial applications.
Material Requirements
IBCs used in pharmaceutical applications must be manufactured from materials that are inert, non-reactive, and non-additive with respect to the stored product. The HDPE must meet USP Class VI biological testing standards, which evaluate the material for in-vivo biological reactivity through implantation and injection tests. This is a significantly higher bar than the FDA 21 CFR 177 compliance required for food-grade containers.
All elastomeric components — valve gaskets, fill cap seals, and any flexible connections — must be similarly validated for pharmaceutical compatibility. Extractables and leachables studies determine what substances migrate from the container material into the stored product under normal and stressed conditions. These studies are product-specific, meaning a container validated for one pharmaceutical ingredient may not be suitable for another.
GMP Documentation Requirements
- Certificate of Analysis from the IBC manufacturer for every lot of containers received
- Material certificates confirming USP Class VI compliance for HDPE and all contact materials
- Extractables and leachables study results specific to the product(s) to be stored
- Validated cleaning procedure with documented evidence of residue removal to acceptable limits
- Container integrity test results (hydrostatic, leakproofness) if required by quality agreement
- Traceability records linking each IBC to its manufacturing lot, cleaning records, and usage history
- Change control documentation for any modification to container specifications or suppliers
Cleaning Validation
Pharmaceutical cleaning validation is a formal process that proves the cleaning procedure removes product residue, cleaning agent residue, and microbial contamination to pre-established acceptance limits. The validation requires a documented cleaning procedure (SOP), at least three consecutive successful cleaning runs, analytical methods for detecting residue at the required sensitivity, defined acceptance criteria based on toxicological data or dose calculations, and ongoing monitoring through periodic verification testing.
Swab sampling and rinse sampling are the two primary methods for verifying cleaning effectiveness on IBC surfaces. Swab testing provides localized contamination data at defined sampling points, while rinse testing provides a composite assessment of the entire inner surface. Most pharmaceutical companies use both methods in combination for comprehensive verification.
Single-Use vs. Reusable IBCs
| Factor | Reusable IBCs | Single-Use (Liner-Based) IBCs |
|---|---|---|
| Upfront cost | Higher (validated container) | Lower (standard container + disposable liner) |
| Per-use cost | Lower (amortized over multiple uses) | Higher (new liner each use) |
| Cleaning requirement | Full validated cleaning between uses | Container cleaning not required; liner is discarded |
| Cross-contamination risk | Managed through validated cleaning | Eliminated — fresh liner each use |
| Waste generation | Lower (container is reused) | Higher (disposable liner waste each use) |
| Documentation burden | Heavy (cleaning records per use) | Moderate (liner CoA per use) |
Temperature-Controlled Storage
Many pharmaceutical ingredients require storage within specified temperature ranges — often 15 to 25°C (controlled room temperature) or 2 to 8°C (refrigerated). IBCs in pharmaceutical service may need insulated jackets, temperature monitoring devices, or storage in temperature-controlled rooms to maintain compliance. Temperature excursion events — even brief ones — can trigger investigations and potentially invalidate the stored material.
In pharmaceutical manufacturing, the container is not just packaging — it is a piece of process equipment that must be validated, controlled, and documented with the same rigor as any other equipment that contacts the product.
Supplier Qualification
Pharmaceutical companies must qualify their IBC suppliers through a formal vendor qualification process. This typically includes an initial assessment questionnaire, an on-site audit of the supplier's manufacturing or reconditioning facility, review of quality management systems (ISO 9001 certification is often a minimum requirement), and establishment of a quality agreement that defines responsibilities, specifications, and change notification requirements.
Used or reconditioned IBCs are generally not acceptable in pharmaceutical applications unless the reconditioning facility itself meets pharmaceutical GMP standards and can provide the full validation documentation package. In practice, most pharmaceutical companies purchase new IBCs directly from validated manufacturers or use single-use liner systems in standard containers.
Our Role in Pharmaceutical Supply
While IBC San Francisco primarily serves industrial, agricultural, and commercial markets, we do supply containers for pharmaceutical-adjacent applications such as laboratory use, non-product-contact water systems, and waste collection. For product-contact pharmaceutical applications, we can refer you to our network of validated pharmaceutical container suppliers who specialize in GMP-compliant IBC systems.
If you are a pharmaceutical operation looking for non-product-contact containers for waste, utilities, or facility maintenance, our standard reconditioned IBCs offer an affordable and sustainable option that meets the needs of these supporting applications.